Single-nucleotide polymorphism-based genetic risk score and patient age at prostate cancer diagnosis by Na, Rong et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
12-2-2019 
Single-nucleotide polymorphism-based genetic risk score and 
patient age at prostate cancer diagnosis 
Rong Na 
Craig Labbate 
Hongjie Yu 
Zhuqing Shi 
Richard J. Fantus 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Rong Na, Craig Labbate, Hongjie Yu, Zhuqing Shi, Richard J. Fantus, Chi-Hsiung Wang, Gerald L. Andriole, 
William B. Isaacs, S Lilly Zheng, Brian T. Helfand, and Jianfeng Xu 
Original Investigation | Genetics andGenomics
Single-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age
at Prostate Cancer Diagnosis
Rong Na, MD, PhD; Craig Labbate, MD; Hongjie Yu, PhD; Zhuqing Shi, PhD; Richard J. Fantus, MD; Chi-HsiungWang, PhD; Gerald L. Andriole, MD, PhD;
William B. Isaacs, MD, PhD; S. Lilly Zheng, MD, PhD; Brian T. Helfand, MD, PhD; Jianfeng Xu, MD, DrPH
Abstract
IMPORTANCE Few studies have evaluated the association between a single-nucleotide
polymorphism–based genetic risk score (GRS) and patient age at prostate cancer (PCa) diagnosis.
OBJECTIVES To test the association between a GRS and patient age at PCa diagnosis and to
compare the performance of a GRS with that of family history (FH) in PCa risk stratification.
DESIGN, SETTING, AND PARTICIPANTS A cohort study of 3225 white menwas conducted as a
secondary analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE)
chemoprevention trial, a 4-year, randomized, double-blind, placebo-controlled multicenter study
conducted fromMarch 2003 to April 2009 to evaluate the safety and efficacy of dutasteride in
reducing PCa events. Participants were confirmed to be cancer free by prostate biopsy (6-12 cores)
within 6 months prior to the study and underwent 10 core biopsies every 2 years per protocol. The
dates for performing data analysis were from July 2016 to October 2019.
INTERVENTIONS Awell-established, population-standardized GRS was calculated for each
participant based on 110 known PCa risk–associated single-nucleotide polymorphisms, which is a
relative risk compared with the general population. Men were classified into 3 GRS risk groups based
on predetermined cutoff values: low (<0.50), average (0.50-1.49), and high (1.50).
MAINOUTCOMESANDMEASURES Prostate cancer diagnosis–free survival amongmen of
different risk groups.
RESULTS Among 3225men (median age, 63 years [interquartile range, 58-67 years]) in the study,
683 (21%) were classified as low risk, 1937 (60%) as average risk, and 605 (19%) as high risk based
on GRS alone. In comparison, 2789 (86%) were classified as low or average risk and 436 (14%) as
high risk based on FH alone. Men in higher GRS risk groups had a PCa diagnosis–free survival rate that
was worse than that of those in the lower GRS risk group (χ2 = 53.3; P < .001 for trend) and in
participants with a negative FH of PCa (χ2 = 45.5; P < .001 for trend). Combining GRS and FH further
stratified overall genetic risk, indicating that 957men (30%) were at high genetic risk (either high
GRS or positive FH), 1667men (52%) were at average genetic risk (average GRS and negative FH),
and 601 men (19%) were at low genetic risk (low GRS and negative FH). Themedian PCa diagnosis–
free survival was 74 years (95% CI, 73-75 years) for men at high genetic risk, 77 years (95% CI, 75 to
>80 years) for men at average genetic risk, andmore than 80 years (95% CI, >80 to >80 years) for
men at low genetic risk. In contrast, the median PCa diagnosis–free survival was 73 years (95% CI,
71-76 years) for men with a positive FH and 77 years (95% CI, 76-79 years) for men with a
negative FH.
(continued)
Key Points
Question Is family history sufficient to
identify men at high risk of
prostate cancer?
Findings In a cohort study of 3225men,
family history alone identified 14% at
high risk of prostate cancer and 86% at
low or average risk; men with a positive
family history of prostate cancer had a
median diagnosis-free survival of 73
years, while men with a negative family
history had a median diagnosis-free
survival of 77 years. A combination of
family history and single-nucleotide
polymorphism–based genetic risk score,
however, identified 30%ofmen at high
genetic risk of prostate cancer, 52% of
men at average genetic risk, and 19% of
men at low genetic risk; the median
diagnosis-free survival was 74 years for
men at high genetic risk, 77 years for
men at average genetic risk, andmore
than 80 years for men at low
genetic risk.
Meaning Combining family history and
genetic risk score can better stratify
inherited risk to develop personalized
prostate cancer screening strategies.
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Abstract (continued)
CONCLUSIONS ANDRELEVANCE This study suggests that a GRS is significantly associated with
patient age at PCa diagnosis. Combining FH and GRSmay better stratify inherited risk than FH alone
for developing personalized PCa screening strategies.
JAMA Network Open. 2019;2(12):e1918145. doi:10.1001/jamanetworkopen.2019.18145
Introduction
Population-based prostate-specific antigen (PSA) screening for prostate cancer (PCa) has been
subject to intense scrutiny owing to the potential harms of overdiagnosis and overtreatment.1
Despite data supporting a mortality benefit from population screening, it remains unclear which
patient groups have themost favorable risk-benefit ratio from screening.2 Currently, all professional
guidelines recommend that age, family history (FH), and race/ethnicity be considered to identify
subsets of men whomay benefit the most from PSA screening.3-6 The US Preventive Services Task
Force recommends a discussion about the benefits and harms of PSA screening for men aged 55 to
69 years and states that FH and race/ethnicity be considered in determining whether earlier PSA
screening is appropriate for individual men.3
Both FH and race/ethnicity are used tomeasure the inherited risk for PCa, a disease with strong
heritability (h2 = 0.57).7 However, FH and race/ethnicity are indirectmeasurements of inherited risk,
which can also be associatedwith environmental exposures.With advances in DNA sequencing and
genotyping technologies and the identification of specific PCa susceptibility genes and variants,8-10 it
is now feasible to also include direct DNAmeasurements as part of inherited risk assessment.
In the last decade, more than 170 PCa risk–associated single-nucleotide polymorphisms (SNPs)
have been identified through multiple large genome-wide association studies (GWASs).10 Despite
small individual associations of these SNPs with PCa risk, they have a stronger cumulative
association.11 Several polygenic risk score methods have been used for measuring the cumulative
association of SNPs.12 To date, all published studies, including those from large case-control
studies,10,13 retrospective analysis of prospective studies,14,15 prostate biopsy cohorts,16,17 and
prospective studies,18 consistently demonstrate associations of polygenic risk scores with PCa risk.
These results provide a basis for a polygenic risk score to be incorporated in the assessment of
inherited risk for PSA screening.
However, few studies of polygenic risk scores have evaluated their association with patient age
at diagnosis of PCa, a critical piece of evidence that will not only strengthen their association with
PCa risk but, more importantly, provide direct evidence for their use in determining patient age for
PSA screening. Seibert and colleagues19 identified 54 SNPs that were associated with patient age at
diagnosis of PCa in the PRACTICAL (Prostate Cancer Association Group to Investigate Cancer
Associated Alterations in the Genome) consortium and then validated the association of a polygenic
hazard score derived from these 54 SNPs with patient age at diagnosis in the Protect (Prostate
Testing for Cancer and Treatment) study.20
In this study, we tested the association between polygenic risk using a genetic risk score (GRS)
and patient age at PCa diagnosis in a randomized clinical trial population. The GRS is an odds ratio
(OR)–weighted and population-standardized score derived from well-established PCa risk–
associated SNPs, and this method has been previously described.12
Methods
Study Population
The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) chemoprevention trial was a
4-year, randomized, double-blind, placebo-controlled study conducted fromMarch 2003 to April
JAMANetworkOpen | Genetics andGenomics SNP-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis
JAMA Network Open. 2019;2(12):e1918145. doi:10.1001/jamanetworkopen.2019.18145 (Reprinted) December 27, 2019 2/12
Downloaded From: https://jamanetwork.com/ by a Washington University - St Louis User  on 03/08/2020
2009 to evaluate the safety and efficacy of dutasteride in reducing PCa events.21 Patients were
between the ages of 50 and 75 years at enrollment, with a PSA level between 2.5 and 10 ng/mL (to
convert to micrograms per liter, multiply by 1.0). Participants were confirmed to be cancer free by
prostate biopsy (6-12 cores) within 6 months prior to the study and underwent 10 core transrectal
ultrasonography-guided biopsies every 2 years per protocol. Participants who did not have a
diagnosis of PCa at completion of the study were censored. High-grade PCa was defined as a Gleason
grade of 3 + 4 or greater. A positive FHwas defined as any first-degree relativewith PCa. The present
genetic study was limited to a cohort of white men who provided written informed consent for
genetic research (3225 of 6729men in the final analysis of the REDUCE trial). The collection of DNA
data was performed prospectively prior to randomization. The institutional review boards at all
participating institutions had approved of the original study. The current retrospective genetic
analysis received approval from theWake Forest School of Medicine Institutional Review Board. We
followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline. The dates for performing data analysis were from July 2016 to October 2019.
PCa Risk–Associated SNPGenotyping
We searched PubMed for PCa GWASs published prior to July 1, 2018, and identified independent PCa
risk–associated SNPs using the following standard criteria: (1) discovered fromGWASs of whitemen,
with at least 1000 cases and 1000 controls in the first stage; (2) confirmed in additional stages with
combined P < 5 × 10−8; and (3) independent, linkage disequilibriummeasurement (r2 < 0.2) between
any pair of SNPs. Of the 174 SNPs thatmet these criteria, 110 PCa risk–associated SNPswere available
directly and indirectly (with imputation using the combined data of the 1000 Genomes Project22
and HapMap323 data) from the genotyping data of the HumanOmniExpress BeadChip (Illumina Inc).
Details regarding these SNPs, including whether they were directly genotyped or imputed, are
described in the eTable in the Supplement, and detailed methods of genotyping, imputation, and
quality control have been previously described.24
Calculation of GRS
An OR-weighted and population-standardized GRS was computed for each participant based on the
110 PCa risk–associated SNPs.12 In brief, a GRS was calculated by multiplying the per-allele OR for
each SNP and normalizing the risk by themean risk expected in the population:
GRS =
n
i = 1
ORigi
Wi
,
Wi = fi 2 OR i2 + 2 fi(1 – fi )OR i + (1 – fi )2,
whereW stands for population, gi stands for the genotype of SNP i for an individual (0, 1, or 2 risk
alleles), ORi stands for the OR of SNP i, and fi stands for the risk allele frequency of SNP i. Allelic ORs
obtained from the external studies and allele frequencies in the gnomAD (Non-Finnish European
population) were used in the calculation. The gnomAD included 55 860 Non-Finnish European
individuals, which to our knowledge is the largest sequenced population of broad European descent.
Because GRS is population standardized, its mean is expected to be 1.0 and its values can be
interpreted as relative risk to the general population. In this study, participants were classified into 3
risk groups prior to the analysis based onGRS values: low (<0.50), average (0.50-1.49), and high risk
(1.50). The cutoff value of 1.5 is determined benchmarked to the PCa risk conferred by a positive
FH. A positive FH is associated with 1.5-fold increased risk for PCa frommultiple
prospective studies.25
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Statistical Analysis
For univariate analysis, differences of quantitative variables among groups were tested using analysis
of variance, and differences of qualitative variables among groups were tested using the χ2 test. The
detection rates of PCa and high-grade PCa among groups were tested using the χ2 test (the trend test
for groups with increasing risk). As PCa-free survival on an age scale is likely to be left-truncated
owing to the fact that patients with a prior PCa diagnosis were not included in the REDUCE trial, we
used a Kaplan-Meier survival analysis package in R, version 3.5.2 (R Project for Statistical Computing)
with a left-truncatedmethod to assess the association between GRS and patient age at PCa
diagnosis. Multivariate analyses were performed to test for the independent effect of factors
associated with PCa diagnosis using a linear regressionmodel (for patient age at diagnosis), a logistic
regressionmodel (for diagnosis of PCa and high-grade PCa), and a Cox proportional hazards
regressionmodel (for PCa diagnosis–free survival time). Statistical analyses were performed using R
version 3.5.2, and a 2-tailed P < .05 was considered statistically significant.
Results
During the 4-year follow-up of 3225 participants included in the genetic subcohort of the REDUCE
trial (1644 participants from the placebo group and 1581 participants from the dutasteride group), a
diagnosis of PCa wasmade for 714 participants (22%), and a diagnosis of high-grade PCa wasmade
for 237 participants (7%). Based on GRSs alone, 683 participants (21%) in the studywere classified as
low risk (<0.5), 1937 (60%) as average risk (0.50-1.49), and 605 (19%) as high risk (1.50). There
was no significant difference in age, FH, and total PSA levels among GRS groups (Table 1).
The GRS risk groups were significantly associated with risk of PCa diagnosis during the 4-year
follow-up (Table 2). The detection rate of PCa was 14% (95 of 683) for participants in the low GRS
risk group, 22% (426 of 1937) for participants in the average GRS risk group, and 32% (193 of 605) for
participants in the high GRS risk group (χ2 = 60.3; P < .001 for trend). Family history was also
significantly associated with PCa diagnosis; the detection rate of PCa was 27% (116 of 436) for men
with a positive FH, slightly higher than for men with a negative FH (598 of 2789 [21%]) (χ2 = 5.83;
P = .02). Fourteen percent of participants (436 of 3225) had a positive FH, and 86% (2789 of 3225)
had a negative FH.
Prostate cancer diagnosis–free survival was estimated for participants based on GRS risk groups
and FH (Table 3). The PCa diagnosis–free survival was significantly worse for participants of higher
GRS risk groups (χ2 = 53.3; log-rank P < .001 for trend; Figure 1A). By the age of 75 years, the
probability of PCa diagnosis–free survival was 0.72 (95% CI, 0.67-0.78) for men in the low GRS risk
group, 0.56 (95% CI, 0.52-0.60) for men in the average risk group, and 0.47 (95% CI, 0.41-0.53) for
men in the high GRS risk group. The median PCa diagnosis-free survival was more than 80 years
(95% CI, >80 to >80 years) for men in the low GRS risk group, 76 years (95% CI, 74 to >80 years) for
men in the average GRS risk group, and 74 years (95% CI, 72-78 years) for men in the high GRS risk
group. Similarly, the PCa diagnosis–free survival was worse for men with a positive FH (χ2 = 21.9;
log-rank P < .001; Figure 1B). The probability of PCa diagnosis-free survival by the age of 75 years was
0.59 (95% CI, 0.56-0.62) for men with a negative FH and 0.43 (95% CI, 0.35-0.52) for men with a
positive FH. Themedian PCa diagnosis–free survival was 77 years (95% CI, 76-79 years) for men with
Table 1. Clinical and Demographic Information of Study Participants at Baseline
Risk Group
Men,
No. (%) (N = 3225)
Age,
Median (IQR), y
Family History,
No. (%)
PSA Level,
Median (IQR), ng/mL
GRS
<0.50 683 (21) 63 (59-68) 82 (12) 5.6 (4.3-7.1)
0.50-1.49 1937 (60) 63 (58-67) 270 (14) 5.7 (4.4-7.3)
≥1.50 605 (19) 63 (58-68) 84 (14) 5.7 (4.4-7.3)
P value NA .14 .23 .91
Abbreviations: GRS, genetic risk score; IQR,
interquartile range; NA, not applicable; PSA, prostate-
specific antigen.
SI conversion factor: To convert PSA tomicrograms per
liter, multiply by 1.0.
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a negative FH and 73 years (95% CI, 71-76 years) for men with a positive FH. More importantly, GRS
risk groups remained a significant factor associated with PCa diagnosis–free survival for men with a
positive FH (χ2 = 7.2; log-rank P = .03 for trend; Figure 1C) and a negative FH (χ2 = 45.5; P < .001 for
trend; Figure 1D).
When GRS and FHwere used jointly to stratify overall genetic risk, 601 of 3225men (19%) were
classified as low genetic risk (lowGRS and negative FH), 1667 of 3225men (52%) as average genetic
risk (average GRS and negative FH), and 957 of 3225 (30%) of men as high genetic risk (either high
GRS or positive FH). Prostate cancer diagnosis–free survival was significantly worse for participants
of higher GRS risk groups (χ2 = 63.0; log-rank P < .001; Figure 1E). The probability of PCa diagnosis-
free survival by the age of 75 years was 0.74 (95% CI, 0.68-0.80) for men at low genetic risk, 0.58
(95% CI, 0.54-0.62) for men at average genetic risk, and 0.46 (95% CI, 0.41-0.52) for men at high
genetic risk. The median PCa diagnosis–free survival was more than 80 years (95% CI, >80 to >80
years) for men at low genetic risk, 77 years (95% CI, 75 to >80 years) in men at average genetic risk,
and 74 years (95% CI, 73-75 years) for men at high genetic risk (Table 3).
A multivariate Cox proportional hazards regression analysis including GRS (continuous
variable), FH, age, and baseline PSA level showed GRS (β = 0.28; P < .001) and FH (β = 0.516;
P < .001) to be independent factors associated with PCa diagnosis–free survival. In addition, there
was no interaction between GRS and FH (χ2 = 0.19; P = .91). Results were similar when the analyses
were performed separately in groups that received placebo or dutasteride (eFigure 1 and eFigure 2 in
the Supplement).
Table 2. Detection Rate of Prostate Cancer by GRS and FH
Risk Group Participants, No. (%)
Patients With PCa, No. (%)
All PCa High-Grade PCa
All Participants (N = 3225)
GRS
<0.50 683 (21) 95 (14) 34 (5)
0.50-1.49 1937 (60) 426 (22) 143 (7)
≥1.50 605 (19) 193 (32) 60 (10)
P value for trend NA <2.2 × 10−16 2.4 × 10−4
All Participants (N = 3225)
Negative FH 2789 (86) 598 (21) 198 (7)
Positive FH 436 (14) 116 (27) 39 (9)
P value NA .02 .17
Participants With Positive FH (n = 436)
GRS
<0.50 82 (19) 15 (18) 6 (7)
0.50-1.49 270 (62) 70 (26) 24 (9)
≥1.50 84 (19) 31 (37) 9 (11)
P value for trend NA 6.01 × 10−5 .40
Participants With Negative FH (n = 2789)
GRS
<0.50 601 (22) 80 (13) 28 (5)
0.50-1.49 1667 (60) 356 (21) 119 (7)
≥1.50 521 (19) 162 (31) 51 (10)
P value for trend NA <2.2 × 10−16 3.12 × 10−4
All Participants (N = 3225)
Negative FH and GRS <0.50 601 (19) 80 (13) 28 (4)
Negative FH and GRS 0.50-1.49 1667 (52) 356 (21) 119 (7)
Positive FH or GRS ≥1.50 957 (30) 278 (29) 90 (9)
P value for trend NA 1.76 × 10−13 4.2 × 10−4
Abbreviations: FH, family history; GRS, genetic risk
score; NA, not applicable; PCa, prostate cancer.
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Similar analyses were performed for high-grade PCa. Genetic risk score group was significantly
associated with risk of high-grade PCa (χ2 = 11.5; P < .001 for trend). In contrast, FH was not
significantly associated with diagnosis of high-grade PCa (χ2 = 1.89; P = .17) (Table 2). The high-grade
PCa diagnosis–free survival was significantly worse for men in higher GRS risk groups (χ2 = 12.8;
log-rank P = .002 for trend; Figure 2A) and with a positive FH (χ2 = 8.8; log-rank P = .003 for trend;
Figure 2B). In stratified analysis based on FH, higher GRS risk groupswere not significantly associated
with high-grade PCa diagnosis–free survival formenwith a positive FH (χ2 = 0.9; log-rank P = .64 for
trend; Figure 2C), but theywere significantly associatedwith high-grade PCa diagnosis–free survival
for men without a FH (χ2 = 11.9; log-rank P = .003 for trend; Figure 2D) and for men with risk
stratified based on a combination of GRS and FH (χ2 = 18.5; log-rank P < .001 for trend; Figure 2E).
Discussion
To our knowledge, this is the first reported study assessing the association of a polygenic risk score
derived fromwell-established risk-associated SNPs with patient age at PCa diagnosis. We found that
higher GRSs were significantly associated with an earlier age at PCa diagnosis. Furthermore, the
association of GRS with patient age at PCa diagnosis was independent of FH. As a result, a
combination of GRS and FH offers a more informative tool for risk stratification than does FH alone,
the current standard of care in the assessment of inherited risk.
Since the first report in 2008 of a strong cumulative association between 5 PCa risk–associated
SNPs discovered from GWASs and PCa risk,11 many studies have consistently demonstrated a
significant association between polygenic risk score and PCa risk.13-18 However, few studies
evaluated its association with patient age at diagnosis of PCa. The only prior study of polygenic risk
Table 3. Prostate Cancer Disease–Free Survival by GRS and FH
Risk Group Men, No. (%)
Cumulative Probability (95% CI) by 75 y of Age Age (95% CI) at 50% Survival, y
All PCa High-Grade PCa All PCa High-Grade PCa
All Participants (N = 3225)
GRS
<0.50 683 (21) 0.72 (0.67-0.78) 0.89 (0.84-0.93) >80 (>80 to >80)a >80 (>80 to >80)a
0.50-1.49 1937 (60) 0.56 (0.52-0.60) 0.80 (0.76-0.84) 76 (74 to >80) >80 (>80 to >80)a
≥1.50 605 (19) 0.47 (0.41-0.53) 0.78 (0.72-0.85) 74 (72 to 78) >80 (>80 to >80)a
All Participants (N = 3225)
Negative FH 2789 (86) 0.59 (0.56-0.62) 0.83 (0.80-0.86) 77 (76 to 79) >80 (>80 to >80)a
Positive FH 436 (14) 0.43 (0.35-0.52) 0.74 (0.65-0.84) 73 (71 to 76) >80 (>80 to >80)a
Participants With Positive FH (n = 436)
GRS
<0.50 82 (19) 0.57 (0.41-0.79) 0.85 (0.75-0.97) >80 (>80 to >80)a >80 (>80 to >80)a
0.50-1.49 270 (62) 0.41 (0.31-0.54) 0.72 (0.60-0.87) 73 (71 to 78) >80 (>80 to >80)a
≥1.50 84 (19) 0.35 (0.22-0.56) 0.69 (0.52-0.92) 70 (66 to 74) >80 (>80 to >80)a
Participants With Negative FH (n = 2789)
GRS
<0.50 601 (22) 0.74 (0.68-0.80) 0.90 (0.86-0.95) >80 (>80 to >80)a >80 (>80 to >80)a
0.50-1.49 1667 (60) 0.58 (0.54-0.62) 0.81 (0.77-0.85) 77 (75 to >80) >80 (>80 to >80)a
≥1.50 521 (19) 0.48 (0.42-0.55) 0.79 (0.73-0.86) 74 (73 to 77) >80 (>80 to >80)a
All Participants (N = 3225)
Negative FH and GRS <0.50 601 (19) 0.74 (0.68-0.80) 0.90 (0.84-0.94) >80 (>80 to >80)a >80 (>80 to >80)a
Negative FH and GRS 0.50-1.49 1667 (52) 0.58 (0.54-0.62) 0.81 (0.77-0.85) 77 (75 to >80) >80 (>80 to >80)a
Positive FH or GRS ≥1.50 957 (30) 0.46 (0.41-0.52) 0.76 (0.72-0.83) 74 (73 to 75) >80 (>80 to >80)a
Abbreviations: FH, family history; GRS, genetic risk score; PCa, prostate cancer.
a The 95% CIs are the same as the age itself becausemore than 80 years was the
upper limit.
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Figure 1. Prostate Cancer Diagnosis–Free Survival Curves Based on 4-Year Follow-up of 3225 Participants
in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) Trial
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Figure 2. High-Grade Prostate Cancer Diagnosis–Free Survival Curves Based on 4-Year Follow-up of 3225 Participants
in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) Trial
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with patient age at PCa diagnosis showed a clear association, but it used a different method of
targeting SNPs based on association with age.19 None of the SNPs used in that study overlappedwith
SNPs previously identified and validated in GWASs for general PCa risk.
The results from the present study add additional critical evidence to support the inclusion of
GRS to FH for better risk stratification. Although FH is currently the criterion standardmeasurement
of assessment of inherited risk and is incorporated intomultiple guidelines (US Preventive Services
Task Force, American Urological Association, European Association of Urology, and National
Comprehensive Cancer Network),3-6 it has multiple pitfalls. Fundamentally, FH is an indirect
measurement of risk based on family members who share only partial genetic information.
Furthermore, a complete FH is often difficult to obtain owing to age, family communication, and
survival status of male relatives. In addition, FH is insufficient to identify individuals with higher
inherited risk and will miss more than 50% of high-risk men in the population. Adding the GRS to FH
creates a more complete genetic risk assessment.
The lack of association between FH and GRS risk groups in the our study is consistent with other
previous studies.10,11,14,25 The exact reason is unclear but is likely due to a combination of themultiple
factors. First, FH reflects both genetic factors and shared household environmental factors. Second,
the GRS captures only partial genetic information from a subset of known risk-associated SNPs.
Other inherited factors such as rare high-penetrant genes (eg, BRCA2, ATM, andHOXB13) and other
yet to be identified common risk-associated SNPs may contribute to FH.25 Third, accurate FH
information is difficult to obtain.
This present study also differs from other studies using the genetic subcohort of the REDUCE
trial in that they all focused on GRS and PCa risk. In 2012, Kader et al14 demonstrated the association
of higher GRSwith higher PCa detection rates during the 4-year follow-up. The GRS in that studywas
based on the first 33 PCa risk–associated SNPs discovered at that time. With more PCa risk–
associated SNPs subsequently identified from GWASs, Chen et al26 assessed the degree and
association of risk reclassification with the increasing number of SNPs used in the calculation of the
GRS (from 17, 34, and 51 to 68 SNPs). Results showed that risk reclassification was minimal with
additional newly identified SNPs and suggested that currently available PCa risk–associated SNPs are
reliable for risk stratification despite potential for the discovery of additional SNPs. Most recently,
using the REDUCE cohort, Yu et al27 assessed the reliability of GRSs using a calibration benchmark.
Results showed that a wide range of GRSs (ie, estimated risks) from the current 110-SNP panel was
corroborated by observed PCa (actual risk) during the 4-year follow-up, with a high calibration slope
and low bias score.
The significant association of GRS and patient age at PCa diagnosis found in the study is unlikely
owing to potential bias in study design. First, the GRSmethod is well established tomeasure the
cumulative effect of SNPs and has been associated with risk of multiple cancers and cardiovascular
disease.10,12,28-30 Second, the PCa risk–associated SNPs (ORs and allele frequencies) used in the GRS
calculation were discovered and confirmed from other large study populations (eTable in the
Supplement). Third, the OR and allele frequency used in the GRS calculation are also derived from
external study populations. Fourth, the dose-response association of GRS risk groups with PCa
diagnosis-free survival curves provides further support for its validity. Fifth, the GRS, as an objective
measurement, is not susceptible to self-reporting bias or to observers’ bias (because the GRS is
unknown to test participants and investigators, practically double-blinded). Furthermore, as a
germline marker, the GRS always precedes any phenotypes (regardless of the study design,
retrospective or prospective) and therefore avoids temporal ambiguity. However, caution should be
exercised when interpreting the estimates of PCa-free survival at the age of 75 years because a
substantial proportion of censored patients (2223 of 3225 [69%]) were censored prior to the age of
75 years without a PCa diagnosis.
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Limitations
Several limitations should be noted. First, only men of European ancestry were included owing to
limited theminority participants available in this study (only 2.3%were black, 1.6% Asian, and 4.0%
American Hispanic); therefore, these data are not yet generalizable to other races/ethnicities.
Second, half the study population was exposed to dutasteride with a potential chemopreventative
effect. We performed survival analysis separately in the groups with or without dutasteride exposure
and obtained similar findings (eFigure 1 and eFigure 2 in the Supplement). Third, our study
population was substantially older than the current recommended ages to begin screening for PCa.
It is yet to be demonstrated whether the data presented in this study can be extrapolated to clinically
important screening decisions in the fifth and sixth decades of life. Fourth, the REDUCE trial included
men with a prior negative biopsy result (owing to a moderately elevated PSA level), and such a
populationmight not be representative of the entire screening population (most people in the
screening population would have a normal PSA level). Further study based on the screening
population is necessary to providemore robust evidence before the clinical use of the GRS for
personalized screening. Fifth, men who participated in this trial might bemotivated in PCa
prevention. Theymay paymore attention to their health conditions, dietary habits, and other factors,
which can lead to potential biases.
Conclusions
This study suggests that the GRS is significantly associated with PCa risk and patient age at PCa
diagnosis, and the association is independent of FH. Combining FH and GRS can better stratify
inherited risk than FH alone. Such an inherited risk stratification strategy will benefit not only men at
high risk by recommending earlier andmore frequent PCa screening but also men at low risk by
recommending decreased or delayed PCa screening.
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SUPPLEMENT.
eTable. Known Prostate Cancer Risk–Associated SNPs Available in the REDUCE Study
eFigure 1. PCa Diagnosis-Free Survival Curves Based on 4-Year Follow-up of 1644 Subjects in the Placebo Arm of
the REDUCE Study and Stratified by GRS Risk Groups (A), Family History (B), GRS Risk Groups in MenWith a
Positive Family History (C), and GRS Risk Groups in MenWith a Negative Family History (D)
eFigure 2. PCa Diagnosis-Free Survival Curves Based on 4-Year Follow-up of 1581 Subjects in the Dutasteride Arm
of the REDUCE Study and Stratified by GRS Risk Groups (A), Family History (B), GRS Risk Groups in MenWith a
Positive Family History (C), and GRS Risk Groups in MenWith a Negative Family History (D)
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